32
Participants
Start Date
July 20, 2023
Primary Completion Date
June 30, 2024
Study Completion Date
December 31, 2024
rhTPO
"Standard treatment options:~Radiotherapy: 95% planning target volume (planning target volume,PTV) ≥45Gy(without simultaneous boost).~Concurrent chemotherapy:~Weekly regimen: paclitaxel 50mg/m2 d1, nedaplatin/cisplatin 25 mg/m2d1, a total of 5 cycles.~Three weeks regimen: paclitaxel 135-175mg/m2 d1, nedaplatin/cisplatin 80mg/m2, a total of 2 cycles.~The active bone marrow was determined by magnetic resonance(magnetic resonance,MR), and the dose limits are: V5\<95%,V10\<85%,V20\<60%,V30\<40%;95%PTV\>45Gy.~rhTPO,15000U ih. qw(during the radiotherapy course)"
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
OTHER
JIANYANG WANG
OTHER